We inform you that Angelini Holding S.p.A. uses cookies (small files saved on your hard disk) to improve your browsing experience on this site. Angelini Holding S.p.A. uses third party cookies that allow third parties to access personal data collected during navigation. By continuing to browse the site, by accessing any area of it or selecting an element of it (for example, an image or a link) you consent to the use of cookies. At the following link you will find our extended information on cookies with a description of the categories present and links to the information of third parties as independent data controllers and you will have the opportunity to decide which cookies to authorize or whether to deny consent to all or only some cookies CONTINUE

R&D programmes

The Angelini group began its R&D experience in the 1960s when it developed original pharmaceutical molecules, and continues today with an investment strategy aimed at constant product innovation.

Research and Development in the pharmaceutical sector

Over the years, Angelini Research has identified active ingredients, such as trazodone and benzydamine, which have become cornerstones of pharmacotherapy.
Currently, research and development programmes are ongoing in the areas of Nervous System Disorders and Diseases and Pain and Inflammation, with a strong commitment to the development of new treatments for the paediatric population
More than 20 clinical studies involving over 2,000 patients in 12 countries are underway.
Angelini Pharma boasts public-private collaborations with national and international Universities and Centres of Excellence, and recognises the important contribution that scientific networking makes to innovation.  An excellent example is that of the collaboration with the Istituto Italiano di Tecnologia [Italian Institute of Technology] (GE), which is famous worldwide for its cutting-edge programmes on computational science and robotics. In 2013, Angelini begun working with this institute in the field of research on the central nervous system. A similarly forward-looking partnership exists with King’s College London, on the topic of analgesia.

Cutting-edge industrial machines

Over the years, Fameccanica’s research and development activities has led to registering over 600 patents, creating innovative solutions for technology, processes and products.
An example of research and development, business and respect for the environment all coming together is seen in Fameccanica’s Glueless project. In 2018, Fameccanica received the “LIFE Best Award” for its Glueless project, having ranked in the top 62 Life+ projects financed by the European Union as part of its support for environmental, nature conservation and climate action projects during the two-year period 2016-2017.
The project centred around the development of new, “glueless” designs for diapers and the technologies that needed to be integrated on the production lines.
Fameccanica’s Glueless project showed how replacing the glue in disposable hygienic-sanitary products with alternative sealing methods can significantly reduce their environmental impact. This contributes to the protection of the environment, as well as making significant savings in the product's final cost.

Fater’s product innovation

Innovation is a fixed element in Fater’s history, which has seen the company create revolutionary products based on fresh concepts.
Pampers Mutandino, the diaper shaped like underwear that is easy-to-wear and easy-to-change, is an example which was launched during the last year. The product comes in different sizes and has doubled the Pampers line.
Cotone, on the other hand, is an innovation in the ‘Lines’ range of feminine hygiene products and panty liners: the part of the product which comes into contact with the skin is made from 100% cotton.
With regards to Ace Detersivo, innovation led to a change in formula with a reduction in dosage needed and 20% less plastic used for the bottle. This translates to approximately 150 fewer tonnes of plastic polluting the environment every year.